Joanna Smart
Directeur/Bestuurslid bij Verso Biosense Group Ltd.
Profiel
Joanna Smart is currently a Director at Verso Biosense Group Ltd.
Prior to this, she was the Executive Chairman and CEO at Oxford Cancer Biomarkers Ltd.
Actieve functies van Joanna Smart
| Bedrijven | Functie | Begin |
|---|---|---|
Verso Biosense Group Ltd.
 Verso Biosense Group Ltd. Financial ConglomeratesFinance Verso Biosense Group Ltd. is a British dormant company that was founded in 2016. The private company is based in Milton, UK. and has subsidiaries in United Kingdom. | Directeur/Bestuurslid | 09-04-2021 |
Eerdere bekende functies van Joanna Smart
| Bedrijven | Functie | Einde |
|---|---|---|
Oxford Cancer Biomarkers Ltd.
 Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Verso Biosense Group Ltd.
Verso Biosense Group Ltd. Financial ConglomeratesFinance Verso Biosense Group Ltd. is a British dormant company that was founded in 2016. The private company is based in Milton, UK. and has subsidiaries in United Kingdom. | Finance |
Oxford Cancer Biomarkers Ltd.
Oxford Cancer Biomarkers Ltd. Hospital/Nursing ManagementHealth Services Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom. | Health Services |
